Provided by Tiger Fintech (Singapore) Pte. Ltd.

Amgen

280.35
+2.861.03%
Pre-market: 280.960.6100+0.22%08:22 EDT
Volume:2.74M
Turnover:764.01M
Market Cap:150.75B
PE:25.62
High:280.54
Open:275.80
Low:273.13
Close:277.49
Loading ...

Amgen Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
15 hours ago

Guggenheim Remains a Hold on Amgen (AMGN)

TIPRANKS
·
Yesterday

Former Horizon CFO Aaron Cox Appointed as New CFO of Galapagos NV, Effective July 7, 2025

Reuters
·
Yesterday

Amgen Price Target Maintained With a $305.00/Share by Cantor Fitzgerald

Dow Jones
·
24 Jun

HSBC Adjusts Price Target on Amgen to $346 From $357

MT Newswires Live
·
24 Jun

Amgen (AMGN) Receives a Buy from Piper Sandler

TIPRANKS
·
24 Jun

Amgen’s Stock Faces Pressure Amid Safety Concerns with MariTide: Hold Rating Maintained

TIPRANKS
·
24 Jun

Sell Rating for Amgen Amid Concerns Over MariTide Trials and Market Positioning

TIPRANKS
·
24 Jun

Amgen’s MariTide Program: Buy Rating Affirmed Amid Promising Phase III Prospects

TIPRANKS
·
24 Jun

BUZZ-Amgen falls; company reports mid-stage data from experimental weight-loss drug

Reuters
·
24 Jun

Amgen down 5% after reporting data from Phase 2 study of MariTide

TIPRANKS
·
24 Jun

Amgen Shares Fall in Volume Spike, Last Down 7%; Clinical Trial Results Released for Company's Experimental Weight-Loss Drug

THOMSON REUTERS
·
24 Jun

Amgen Down Over 6%, on Pace for Largest Percent Decrease Since November 2024 -- Data Talk

Dow Jones
·
24 Jun

Amgen Announces Promising Results from Phase 2 Study of MariTide, Showing Significant Weight Loss and Cardiometabolic Improvements in Obesity Treatment

Reuters
·
24 Jun

Amgen Inc - Maritime Phase 3 Chronic Weight Management Studies Are Actively Enrolling

THOMSON REUTERS
·
24 Jun

Amgen- Phase 3 Studies in People Living With Atherosclerotic Cardiovascular Disease, Heart Failure and Obstructive Sleep Apnea to Be Initiated in 2025

THOMSON REUTERS
·
24 Jun

Amgen Inc - Maritide Shows About 20% Weight Loss in Obesity Without T2d

THOMSON REUTERS
·
24 Jun

Results From Amgen's Phase 2 Obesity Study of Monthly Maritide Presented at the American Diabetes Association 85TH Scientific Sessions

THOMSON REUTERS
·
24 Jun

Amgen - in People Living With Obesity With Type 2 Diabetes, Maritide Demonstrated up to About 17% Average Weight Loss and Robust Hba1c Improvements

THOMSON REUTERS
·
24 Jun

American Express, Amgen Share Losses Contribute To Dow's 100-Point Drop

Dow Jones
·
24 Jun